License Agreement Turns Biotech Partners Into Rivals

Law360, New York (December 15, 2006, 12:00 AM EST) -- Biotech partners in a transatlantic licensing dispute are on their way to arbitration after California’s Spectrum Pharmaceuticals Inc. accused its German partner of cutting it out of a multimillion dollar sublicensing agreement.

At stake is control over satraplatin, a promising prostate-cancer drug co-developed by Spectrum and its partner, GPC Biotech AG, which allegedly cut Spectrum out of $59 million worth of sublicensing deals with another German firm, Pharmion GmbH.

According to Irvine, Calif.-based Spectrum, GPC Biotech’s deal with Pharmion violated their licensing agreement, effectively ending it....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.